US · MBAI · MEDICAL - DIAGNOSTICS & RESEARCH
Check-Cap Ltd. Ordinary Share (MBAI) intrinsic value and stock valuation
$2.00as of 2026-11-21 · Mkt cap 9.13M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Check-Cap Ltd. Ordinary Share DCF and intrinsic value
InvestorsCraft values MBAI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MBAI’s statements →
Check-Cap Ltd. Ordinary Share Graham Number
Graham Number: $2.87d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2021–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-2.37M | -$-25.95M | -$-19.29M | -$-20.03M | -$-17.32M |
| Net income | $4.14M | -$-25.15M | -$-17.57M | -$-19.11M | -$-17.2M |
| EPSd | $664.5K | -$-4.3M | -$-3M | -$-3.37M | -$-3.03M |
| Operating cash flow | -$-50K | -$-8M | -$-16.95M | -$-18.71M | -$-16.26M |
| Capital expenditure | $0.00 | $0.00 | -$-80K | -$-490K | -$-1.01M |
| Free cash flow | -$-50K | -$-8M | -$-17.04M | -$-19.19M | -$-17.27M |
| Total assets | $7.49M | $380K | $25M | $45.4M | $55.7M |
| Total debt | $20K | $140K | $0.00 | $960K | $1.15M |
| Net debt | $10K | $140K | -$-8.84M | -$-3.13M | -$-25.31M |
| Total equity | $3.44M | -$-1.45M | $23.7M | $41.3M | $50.7M |
| Cash and short-term investments | $220K | $270K | $24.8M | $41.7M | $51.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $0.00 | $0.00 | $8.31M | $14.3M | $12.4M |
| Selling, general and administrative expenses | $2.34M | $9.3M | $9.46M | $5.65M | $4.94M |
| Other expenses | $30K | $16.7M | $1.51M | $120K | $40K |
| Operating expenses | $2.37M | $26M | $19.3M | $20M | $17.3M |
| Cost and expenses | $2.37M | $26M | $19.3M | $20M | $17.3M |
| Interest income | $170K | $810K | $1.77M | $1.05M | $100K |
| Interest expense | $180K | $10K | $10K | $10K | $10K |
| Depreciation and amortization | $30K | $160K | $210K | $400K | $200K |
| Ebitda | $4.36M | -$-24.98M | -$-17.34M | -$-18.69M | -$-16.98M |
| Operating income | -$-2.37M | -$-25.95M | -$-19.29M | -$-20.03M | -$-17.32M |
| Total other income/expenses, net | $6.51M | $800K | $1.72M | $930K | $120K |
| Income before tax | $4.14M | -$-25.15M | -$-17.57M | -$-19.11M | -$-17.2M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $4.14M | -$-25.15M | -$-17.57M | -$-19.11M | -$-17.2M |
| Weighted average shares outstanding | $6.23M | $5.85M | $5.85M | $5.67M | $5.67M |
| Weighted average diluted shares outstanding | $6.23M | $5.85M | $5.85M | $5.67M | $5.67M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $220K | $270K | $24.8M | $41.7M | $51.6M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $220K | $270K | $24.9M | $42.6M | $52.8M |
| Property, plant and equipment, net | $20K | $110K | $160K | $2.81M | $2.91M |
| Goodwill and intangible assets | $730K | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $6.53M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $7.27M | $110K | $160K | $2.81M | $2.91M |
| Total assets | $7.49M | $380K | $25M | $45.4M | $55.7M |
| Accounts payable | $790K | $490K | $140K | $950K | $1.05M |
| Short-term debt | $20K | $120K | $0.00 | $340K | $350K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $4.05M | $1.81M | $1.33M | $3.41M | $4.04M |
| Long-term debt | $0.00 | $20K | $0.00 | $630K | $800K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $20K | $0.00 | $720K | $930K |
| Capital lease obligations | $20K | $140K | $0.00 | $960K | $1.15M |
| Total liabilities | $4.05M | $1.83M | $1.33M | $4.13M | $4.97M |
| Common stock | $83.9M | $83.8M | $83.8M | $83.7M | $68.8M |
| Retained earnings | -$-165.87M | -$-170.01M | -$-144.86M | -$-127.29M | -$-108.19M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $3.44M | -$-1.45M | $23.7M | $41.3M | $50.7M |
| Total investments | $6.74M | $270K | $15.9M | $37.6M | $25.1M |
| Total debt | $20K | $140K | $0.00 | $960K | $1.15M |
| Net debt | $10K | $140K | -$-8.84M | -$-3.13M | -$-25.31M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $4.14M | -$-25.15M | -$-17.57M | -$-19.11M | -$-17.2M |
| Depreciation and amortization | $30K | $160K | $210K | $400K | $200K |
| Stock-based compensation | $0.00 | $10K | -$-60K | $880K | $490K |
| Change in working capital | -$-4.17M | $480K | -$-1.27M | -$-260K | $240K |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $2.22M | $500K | -$-850K | $210K | $360K |
| Net cash provided by operating activities | -$-50K | -$-8M | -$-16.95M | -$-18.71M | -$-16.26M |
| Investments in property, plant and equipment | $0.00 | $0.00 | -$-80K | -$-490K | -$-1.01M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $50K | -$-840K | $21.4M | -$-12.51M | -$-16.01M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $8.85M | $31.8M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $0.00 | $0.00 | $0.00 | $8.85M | $51M |
| Net change in cash | -$-50K | -$-24.49M | $4.4M | -$-22.36M | $18.8M |
| Cash at end of period | $220K | $270K | $8.84M | $4.44M | $26.8M |
| Operating cash flow | -$-50K | -$-8M | -$-16.95M | -$-18.71M | -$-16.26M |
| Capital expenditure | $0.00 | $0.00 | -$-80K | -$-490K | -$-1.01M |
| Free cash flow | -$-50K | -$-8M | -$-17.04M | -$-19.19M | -$-17.27M |
Line items
Line items
Line items
About Check-Cap Ltd. Ordinary Share
Check-Cap Ltd. is a medical diagnostics entity currently in its clinical development phase, dedicated to advancing screening solutions that utilize capsule-based technology. This firm was established in 2004 and conducts its primary operations from Isfiya, Israel.
- CEO
- David Lontini
- Employees
- 85
- Beta
- 0.79
Explore
Frequently asked questions
What is the intrinsic value of Check-Cap Ltd. Ordinary Share (MBAI)?
InvestorsCraft does not currently publish an intrinsic value for MBAI. How the IC value is calculated.
Is MBAI undervalued?
InvestorsCraft does not publish an undervaluation signal for MBAI at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.